Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Goldnboy1on Jun 29, 2023 5:16am
297 Views
Post# 35519890

Breast Cancer Updates - Any Day Now!!

Breast Cancer Updates - Any Day Now!!

According to this analyst article from back in March...

Speculative Buy - $8.50 Target Price...

Key statements from the analyst:

- Phase 2 HR+/Her2 Breast Cancer Results
- Company is seeking Co-Development Partners that will allow them to stop using ATM issuances to fund the company.

Pretty important to note, this week is the final week of Q2. Activity we have been provided thus far feels like the tip of the iceberg. Bring on impressive breast cancer results and a huge fundraising deal with big pharma. 

Often stocks will put out their best news just ahead of a long weekend. Get the stock rocking. Then everyone talks over the long weekend and you get another bump Up after word spreads.

If this were to occur, today could be that day. Have to think in the very least by the end of July the Brest Cancer results are out and by the end of August the fundraising strategy disclosed.

Despite current healthy volatility, what a wonderful time to be an ONC shareholder! Added 3,000 more shares today. Not a ton, but it's all going to count soon enough! 33k and counting! Show me $10 this summer!!

https://www.cantechletter.com/2023/03/oncolytics-biotech-has-a-big-upside-says-leede-jones-gable/amp/

<< Previous
Bullboard Posts
Next >>